Neurexpert was founded in 2011 to provide assays delivering data on compound potency and efficacy at the native target. These assays bridge a gap between in vitro and in vivo screens, confirming mechanism of
action and provide essential functional and mechanistic data on the neural mechanisms underlying higher brain functions such as cognition and sensory processing.
Our expertise can assist project progression at all stages of the drug discovery process, from target validation and early stage screening through to functional biomarker studies to aid clinical development.
Stuart Neale, PhD, Chief Executive Officer, is an electrophysiologist and neuroscientist with over 20 years’ experience studying physiological variables in pharmaceutical, academic and clinical research environments. He has extensive expertise in developing electrophysiology assays for drug discovery in companies ranging from start-ups through to large pharma, and successfully integrating these into the output of multidisciplinary project teams engaged in drug discovery and early development activities across a range of diseases of the nervous system.
Tom Salt, PhD, Chief Scientific Officer, is a Fellow of the British Pharmacological Society, and is Emeritus Professor at University College London (UCL). His research encompasses neurotransmitter pharmacology in the visual and somatosensory/pain systems, and the functional consequences of retinal degenerations in eye diseases. Tom has published over 200 research and review papers including in journals such as Nature, Science, Nature Neuroscience, PNAS, and is a member of several editorial boards. He has worked in the pharmaceutical industry, and has acted as a consultant and adviser to industry.
Martin Gunthorpe, PhD, Scientific & Business Development Consultant, has over 20 years’ experience in research, drug discovery, and development spanning from idea to approved medicine, primarily in the neurosciences therapeutic area (SmithKline Beecham, GlaxoSmithKline, BioCrea GmbH, Alterion Consulting Ltd). In addition to extensive leadership experience of preclinical and clinical projects, Martin was also the pharmacology expert supporting the NDA, regulatory approval and launch activities for retigabine (Trobalt/Ezogabine), an antiepileptic drug with a novel mechanism of action, with the FDA and EMA.
Mark Cunningham, PhD, Consultant: Neural Networks and Oscillations, is Professor of Neuronal Dynamics at Newcastle University. He is a recognised expert in the application of electrophysiological techniques to study neuronal networks. His research focuses on understanding the generation of synchonised activity in these networks of relevance to disorders including epilepsy and cognitive dysfunction. Mark sits on the Scientific Advisory Committee for Epilepsy Research UK, and has acted on advisory boards and as a consultant to numerous pharmaceutical companies.